Send to

Choose Destination
Aliment Pharmacol Ther. 1997 Apr;11(2):273-82.

Clinical economics review: Helicobacter pylori-associated peptic ulcer disease.

Author information

Division of Medicine, St James's University Hospital, Leeds, UK.


The high prevalence and chronic nature of peptic ulcer disease have traditionally resulted in a major economic burden on health care systems. In 1991, for example, peptic ulcer disease was estimated to account for over one-third of all National Health Service expenditure on gastrointestinal diseases. It is now well established that elimination of Helicobacter pylori can lead to a dramatic reduction in gastroduodenal ulcer relapse, with obvious clinical benefits. This review considers the economic implications of the use of H. pylori eradication therapy in peptic ulcer disease.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center